NL300986I2 - lanadelumab - Google Patents

lanadelumab Download PDF

Info

Publication number
NL300986I2
NL300986I2 NL300986C NL300986C NL300986I2 NL 300986 I2 NL300986 I2 NL 300986I2 NL 300986 C NL300986 C NL 300986C NL 300986 C NL300986 C NL 300986C NL 300986 I2 NL300986 I2 NL 300986I2
Authority
NL
Netherlands
Prior art keywords
lanadelumab
Prior art date
Application number
NL300986C
Other languages
English (en)
Other versions
NL300986I1 (nl
Original Assignee
Dyax Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dyax Corp filed Critical Dyax Corp
Publication of NL300986I1 publication Critical patent/NL300986I1/nl
Publication of NL300986I2 publication Critical patent/NL300986I2/nl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/0004Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
NL300986C 2010-01-06 2019-05-07 lanadelumab NL300986I2 (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29261410P 2010-01-06 2010-01-06
PCT/US2011/020377 WO2011085103A2 (en) 2010-01-06 2011-01-06 Plasma kallikrein binding proteins

Publications (2)

Publication Number Publication Date
NL300986I1 NL300986I1 (nl) 2019-05-15
NL300986I2 true NL300986I2 (nl) 2019-11-21

Family

ID=44306145

Family Applications (1)

Application Number Title Priority Date Filing Date
NL300986C NL300986I2 (nl) 2010-01-06 2019-05-07 lanadelumab

Country Status (20)

Country Link
US (10) US8822653B2 (nl)
EP (3) EP3459564B1 (nl)
JP (5) JP6037841B2 (nl)
AU (1) AU2011204349C1 (nl)
CA (3) CA3168591A1 (nl)
CY (3) CY1122268T1 (nl)
DK (2) DK2521568T3 (nl)
ES (2) ES2905545T3 (nl)
FR (1) FR19C1029I2 (nl)
HR (2) HRP20220107T1 (nl)
HU (3) HUE039605T2 (nl)
LT (3) LT3459564T (nl)
LU (1) LUC00115I2 (nl)
NL (1) NL300986I2 (nl)
NO (1) NO2019020I1 (nl)
PL (2) PL2521568T3 (nl)
PT (2) PT2521568T (nl)
RS (2) RS57870B1 (nl)
SI (2) SI3459564T1 (nl)
WO (1) WO2011085103A2 (nl)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US20050222023A1 (en) * 2002-02-07 2005-10-06 Hans-Peter Hauser Albumin-fused kunitz domain peptides
WO2003103475A2 (en) 2002-06-07 2003-12-18 Dyax Corp. Prevention and reduction of blood loss
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
CN102307594A (zh) 2009-01-06 2012-01-04 戴埃克斯有限公司 用激肽释放酶抑制剂治疗粘膜炎
HUE039605T2 (hu) 2010-01-06 2019-01-28 Dyax Corp Plazma kallikreint kötõ proteinek
KR102320178B1 (ko) 2011-01-06 2021-11-02 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질
EP3320922A1 (en) * 2011-06-10 2018-05-16 Ionis Pharmaceuticals, Inc. Methods for modulating kallikrein (klkb1) expression
AU2012275096B2 (en) 2011-06-29 2016-02-04 Ionis Pharmaceuticals, Inc. Methods for modulating kallikrein (KLKB1) expression
JP6253578B2 (ja) * 2011-07-22 2017-12-27 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 阻害性抗第xii/xiia因子モノクローナル抗体及びそれらの使用
CA3209608A1 (en) 2013-01-20 2014-07-24 Takeda Pharmaceutical Company Limited Evaluation and treatment of pkal-mediated disorders
PT2946206T (pt) * 2013-01-20 2019-04-22 Dyax Corp Avaliação, ensaios e tratamento de distúrbios mediados por pkal
CA2906624A1 (en) 2013-03-15 2014-09-25 Dyax Corp. Anti-plasma kallikrein antibodies
CN103336127A (zh) * 2013-05-20 2013-10-02 许瑞安 一种早期肝病、肝纤维化和肝硬化指示剂与诊断剂
WO2015031679A2 (en) 2013-08-28 2015-03-05 Isis Pharmaceuticals, Inc. Modulation of prekallikrein (pkk) expression
KR20230054745A (ko) 2013-10-21 2023-04-25 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 시스템 바이오마커를 결정하기 위한 검정법
EP3913364A1 (en) 2013-10-21 2021-11-24 Dyax Corp. Diagnosis and treatment of autoimmune diseases
CA2937329C (en) * 2014-01-21 2022-05-31 Dyax Corp. Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema
WO2015148790A1 (en) * 2014-03-27 2015-10-01 Dyax Corp. Compositions and methods for treatment of diabetic macular edema
DK3137091T3 (da) 2014-05-01 2021-01-25 Ionis Pharmaceuticals Inc Konjugater af modificerede antisense-oligonukleotider og anvendelse deraf til modulation af pkk-ekspression
SG11201704548PA (en) 2014-12-05 2017-07-28 Memorial Sloan Kettering Cancer Center Antibodies targeting b-cell maturation antigen and methods of use
CN107208047B (zh) 2014-12-05 2021-09-21 纪念斯隆-凯特琳癌症中心 靶向b-细胞成熟抗原的嵌合抗原受体及其用途
US11390687B2 (en) 2015-01-02 2022-07-19 Takeda Pharmaceutical Company Limited Bispecific antibodies against plasma kallikrein and Factor XII
EP3286226A4 (en) * 2015-03-30 2018-12-05 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack
KR20180096567A (ko) 2015-07-21 2018-08-29 다이액스 코포레이션 Xiia 인자의 단일클론 항체 저해제
PT3365685T (pt) 2015-10-19 2021-03-01 Dyax Corp Imunoensaio para detetar cininogénio de elevada massa molecular clivado
NZ744233A (en) 2015-12-11 2023-11-24 Takeda Pharmaceuticals Co Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
CN108475034B (zh) * 2015-12-25 2021-04-13 佳能株式会社 定影装置和成像装置
WO2017205820A1 (en) * 2016-05-27 2017-11-30 The Board Of Trustees Of The Leland Stanford Junior University Affinity matured broad spectrum antibodies to hepatitis c virus
KR20220154245A (ko) 2016-09-16 2022-11-21 다케다 파머수티컬 컴패니 리미티드 접촉 활성화 시스템과 연관된 질환을 위한 대사물질 바이오마커
CA3037154A1 (en) 2016-09-16 2018-03-22 Dyax Corp. Protein biomarkers for diseases associated with the contact activation system
AU2017325999C1 (en) 2016-09-16 2024-03-07 Takeda Pharmaceutical Company Limited RNA biomarkers for hereditary angioedema
KR20240063204A (ko) 2017-02-17 2024-05-10 프레드 허친슨 캔서 센터 Bcma 관련 암 및 자가면역 장애의 치료를 위한 조합 요법
AU2018221172A1 (en) 2017-02-17 2019-09-05 Adimab, Llc Monoclonal antibodies and cocktails for treatment of Ebola infections
US11560372B2 (en) 2017-04-18 2023-01-24 Takeda Pharmaceutical Company Limited Heterocyclic compounds useful as modulators of acetylcholine receptors
SG11202003501XA (en) 2017-11-01 2020-05-28 Juno Therapeutics Inc Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
CN111902159A (zh) 2017-11-01 2020-11-06 朱诺治疗学股份有限公司 对b细胞成熟抗原(bcma)具有特异性的嵌合抗原受体
US11957745B2 (en) 2018-02-22 2024-04-16 Vanderbilt University Human Japanese Encephalitis Virus antibodies and methods of use therefor
US11754570B2 (en) 2019-04-16 2023-09-12 Takeda Pharmaceutical Company Limited Methods for quantitation of functional C1 esterase inhibitor (FC1-INH)
US11634501B2 (en) 2019-07-19 2023-04-25 Oncoresponse, Inc. Immunomodulatory antibodies and methods of use thereof
EP4076500A4 (en) * 2019-12-19 2023-12-27 Blaze Bioscience, Inc. METHOD FOR TREATING VASCULAR LESIONS AND MALFORMATIONS
WO2021158960A1 (en) * 2020-02-07 2021-08-12 Ellebedy Ali Antibodies protective against influenza b
WO2021198534A1 (en) 2020-04-04 2021-10-07 Oxurion NV Plasma kallikrein inhibitors for use in the treatment of coronaviral disease
WO2022087458A1 (en) * 2020-10-23 2022-04-28 Asher Biotherapeutics, Inc. Fusions with cd8 antigen binding molecules for modulating immune cell function
KR20230125809A (ko) * 2020-12-18 2023-08-29 바이오아르디스 엘엘씨 Fap 결합 분자 및 이의 사용
WO2022156798A1 (zh) * 2021-01-25 2022-07-28 成都康弘生物科技有限公司 一种抗体及其用途
MX2024004011A (es) 2021-10-01 2024-07-01 Adarx Pharmaceuticals Inc Composiciones moduladoras de precalicreína y métodos de uso de estas.
WO2023144030A1 (en) 2022-01-31 2023-08-03 Oxurion NV Plasma kallikrein inhibitor therapy for anti-vegf sensitization
WO2023148016A1 (en) 2022-02-04 2023-08-10 Oxurion NV Biomarker for plasma kallikrein inhibitor therapy response
WO2024003617A2 (en) 2022-06-30 2024-01-04 Takeda Pharmaceutical Company Limited Protein biomarkers for lanadelumab treatment

Family Cites Families (244)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR6915369D0 (pt) * 1969-02-27 1973-03-13 Bayer Ag Emprego de inibidores biologicos de proteases para conservacao de orgaos tecidos e alimentos
US3691016A (en) * 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
CA1023287A (en) * 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
DE2619246A1 (de) * 1976-04-30 1977-11-10 Bayer Ag Desamino-derivate des kallikrein- trypsin-inhibitors, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
US4195128A (en) * 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
DE2654124A1 (de) * 1976-11-29 1978-06-01 Bayer Ag Derivate des trypsin-kallikrein-inhibitors aus rinderorganen (bpti) mit proteasenhemmwirkung und antiphlogistischer wirkung, ihre herstellung und ihre verwendung als arzneimittel
US4330440A (en) * 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) * 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) * 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4289747A (en) 1978-12-26 1981-09-15 E-Y Laboratories, Inc. Immunological determination using lectin
AT359653B (de) * 1979-02-15 1980-11-25 Immuno Ag Verfahren zur herstellung eines gewebekleb- stoffes
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) * 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
AU560584B2 (en) * 1983-07-28 1987-04-09 Bayer Aktiengesellschaft Homologues of aprotinin
US4657893A (en) * 1984-05-09 1987-04-14 Syntex (U.S.A.) Inc. 4H-3,1-benzoxazin-4-ones and related compounds and use as enzyme inhibitors
US4845242A (en) * 1987-04-28 1989-07-04 Georgia Tech Research Corporation Isocoumarins with basic substituents as serine proteases inhibitors, anticoagulants and anti-inflammatory agents
US4609725A (en) * 1984-10-09 1986-09-02 Merck & Co., Inc. Cardiac atrial peptides
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US5444156A (en) * 1985-07-12 1995-08-22 Temple University-Of The Commonwealth System Of Higher Education Monoclonal antibodies to human plasma prekallikrein
CA1312564C (en) 1985-07-12 1993-01-12 Robert W. Colman Monoclonal antibodies to human plasma prekallikrein and methods of preparing and using same
JPH0623113B2 (ja) 1986-01-31 1994-03-30 浩 前田 癌性胸・腹水貯留抑制剤
US4868103A (en) 1986-02-19 1989-09-19 Enzo Biochem, Inc. Analyte detection by means of energy transfer
WO1987005396A1 (en) * 1986-03-03 1987-09-11 Brigham And Women's Hospital A method for evaluating nephrotoxicity
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0255011A3 (en) 1986-07-29 1988-11-23 Miles Inc. Human inter-alpha-trypsin inhibitor gene
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5260203A (en) * 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JPH0779702B2 (ja) 1986-11-17 1995-08-30 サイオス ノバ インコーポレイテッド 組換えアルツハイマーアミロイドタンパク
EP0285123A3 (en) 1987-04-03 1989-02-01 Stabra AG A method for complete mutagenesis of nucleic acids
US4966852A (en) * 1987-07-23 1990-10-30 Monsanto Company DNA clone of human tissue factor inhibitor
US5106833A (en) * 1987-07-23 1992-04-21 Washington University Coagulation inhibitors
IL87172A (en) 1987-07-23 1994-12-29 Univ Washington A method of inhibiting the isolation of a purer tissue factor
GB2208511A (en) 1987-08-07 1989-04-05 Bayer Ag Variants of bovine pancreatic trypsin inhibitor produced by recombinant dna technology
DK225488D0 (da) 1988-04-26 1988-04-26 Novo Industri As Polypeptid
ES2035317T5 (es) 1987-11-09 1998-03-16 Becton Dickinson Co Metodo para analizar celulas hematopoyeticas en una muestra.
IL87171A (en) 1987-11-23 1995-08-31 Monsanto Co ANDC of human tissue factor inhibitor
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5663143A (en) * 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
US5045452A (en) * 1988-09-02 1991-09-03 Brigham And Women's Hospital Method for evaluating nephrotoxicity
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
US7078383B2 (en) 1988-09-02 2006-07-18 Dyax Corp. ITI-D1 Kunitz domain mutants as HNE inhibitors
US5372933A (en) * 1988-10-03 1994-12-13 The Scripps Research Institute Polypeptides that mimic receptor-induced binding sites, and methods of using same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2066033T3 (es) 1989-05-13 1995-03-01 Bayer Ag Inhibidores de las proteinasas, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
US5030002A (en) 1989-08-11 1991-07-09 Becton, Dickinson And Company Method and apparatus for sorting particles with a moving catcher tube
DK408089D0 (da) * 1989-08-18 1989-08-18 Novo Nordisk As Proteiner
US5378614A (en) * 1989-08-18 1995-01-03 Novo Nordisk A/S Vector and method for making tissue factor pathway inhibitor (TFPI) analogues in yeast
US5278285A (en) * 1990-02-01 1994-01-11 Bayer Aktiengesellschaft Variant of Kunitz-type inhibitor derived from the α3-chain of human type VI collagen produced by recombinant DNA technology
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
JPH06508511A (ja) 1990-07-10 1994-09-29 ケンブリッジ アンティボディー テクノロジー リミティド 特異的な結合ペアーの構成員の製造方法
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
IE76732B1 (en) 1990-08-07 1997-11-05 Becton Dickinson Co One step test for absolute counts
US5278144A (en) * 1990-09-04 1994-01-11 Cor Therapeutics, Inc. Antithrombosis agents
US5583107A (en) * 1990-09-04 1996-12-10 Cor Therapeutics, Inc. Agents affecting thrombosis and hemostasis
IL99585A0 (en) 1990-10-01 1992-08-18 Novo Nordisk As Aprotinin analogues,their production and pharmaceutical compositions containing them
US5409895A (en) * 1990-11-13 1995-04-25 Mochida Pharmaceutical Co., Ltd. Protease inhibitory polypeptides derived from urinary trypsin inhibitor and compositions thereof
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5304122A (en) 1991-02-14 1994-04-19 Medtronic, Inc. Method for providing a restenosis model in porcine coronary arteries
US5370901A (en) 1991-02-15 1994-12-06 Bracco International B.V. Compositions for increasing the image contrast in diagnostic investigations of the digestive tract of patients
EP0575485A1 (en) 1991-03-01 1993-12-29 Dyax Corp. Process for the development of binding mini-proteins
US20030223977A1 (en) 1991-03-01 2003-12-04 Ley Arthur Charles Kunitz domain mutants as cathepsin G inhibitors
JP3672306B2 (ja) 1991-04-10 2005-07-20 ザ スクリップス リサーチ インスティテュート ファージミドを使用するヘテロ二量体受容体ライブラリー
US5166133A (en) * 1991-04-17 1992-11-24 Cetus Corporation Method for inhibing adhesion of white blood cells to endothelial cells
AU675916B2 (en) 1991-06-14 1997-02-27 Genentech Inc. Method for making humanized antibodies
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
AU3061092A (en) 1991-10-31 1993-06-07 Salk Institute Biotechnology/Industrial Associates, Inc., The Recombinant amyloid precursor protein inhibitor domain and treatment of various disease states
IL104327A0 (en) * 1992-01-07 1993-05-13 Novo Nordisk As Variant of human kunitz-type protease inhibitor
IL104325A (en) 1992-01-07 2000-10-31 Novo Nordisk As Variants of human kunitz-type protease inhibitor domain II of tissue factor pathway inhibitor (TFPI) pharmaceutical compositions containing them a DNA construct encoding them their expression vectors a cell containing said DNA constructs and methods for the production of all the above
IL104324A0 (en) 1992-01-07 1993-05-13 Novo Nordisk As Variant of human kunitz-type protease inhibitor
IL104326A0 (en) 1992-01-07 1993-05-13 Novo Nordisk As Variant of human kunitz-type protease inhibitor
IL104314A0 (en) * 1992-01-07 1993-05-13 Novo Nordisk As Human kunitz-type protease inhibitor and variants thereof,their production and pharmaceutical compositions containing them
CA2087413A1 (en) 1992-01-17 1993-07-18 Joseph R. Lakowicz Fluorescent energy transfer immunoassay
US5212091A (en) * 1992-03-02 1993-05-18 Monsanto Company Method of producing tissue factor pathway inhibitor
US6063764A (en) * 1992-06-01 2000-05-16 Washington University & Chiron Corp. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
SE9201984D0 (sv) 1992-06-29 1992-06-29 Pharmacia Biosensor Ab Improvement in optical assays
JPH07509229A (ja) * 1992-07-13 1995-10-12 コルバス・インターナショナル、インコーポレイテッド ウシ膵トリプシン阻害因子から誘導される因子Xaの阻害因子
AU5684594A (en) * 1992-12-02 1994-06-22 Novo Nordisk A/S Novel human amyloid protein precursor homologue and kunitz-type inhibitors
US5436153A (en) * 1992-12-02 1995-07-25 Sprecher; Cindy A. Human amyloid protein precursor homolog and Kunitz-type inhibitor
US5426224A (en) * 1993-03-18 1995-06-20 The University Of North Carolina At Chapel Hill Mammalian DNA topoisomerase II inhibitor and method
WO1995007986A1 (en) * 1993-09-14 1995-03-23 Genentech, Inc. Pharmaceutical compositions containing ecotin and homologs thereof
US5455338A (en) * 1993-11-05 1995-10-03 Zymogenetics, Inc. DNA encoding novel human kunitz-type inhibitors and methods relating thereto
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US5446090A (en) * 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5759548A (en) * 1993-11-30 1998-06-02 Lxr Biotechnology Inc. Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof
US5827690A (en) * 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
JP3805785B2 (ja) 1994-01-11 2006-08-09 ダイアックス コープ. カリクレイン阻害クニッツドメイン蛋白質およびその相同体
CA2180954C (en) 1994-01-11 2007-03-20 William Markland Inhibitors of human plasmin derived from the kunitz domains
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US5795954A (en) * 1994-03-04 1998-08-18 Genentech, Inc. Factor VIIa inhibitors from Kunitz domain proteins
ATE186305T1 (de) * 1994-06-02 1999-11-15 Merrell Pharma Inc Perfluoroalkyll ketone, inhibitoren von elastase und prozess zur deren herstellung
EP0774001B1 (en) * 1994-08-05 2002-10-16 Chiron Corporation Production of tissue factor pathway inhibitor
US5589359A (en) 1994-08-05 1996-12-31 Chiron Corporation Chimeric proteins
US5648331A (en) * 1994-08-26 1997-07-15 G.D. Searle & Co. Method of inhibiting tissue ischemia and reperfusion injury
WO1996012021A2 (en) * 1994-10-18 1996-04-25 Corvas International, Inc. Nematode-extracted serine protease inhibitors and anticoagulant proteins
US6159938A (en) 1994-11-21 2000-12-12 Cortech, Inc. Serine protease inhibitors comprising α-keto heterocycles
JPH10510540A (ja) 1994-12-12 1998-10-13 オメロス メディカル システムズ,インコーポレーテッド 灌注用溶液並びに疼痛、炎症及びけいれんの抑制法
EP1609477B1 (en) * 1994-12-12 2011-11-09 Omeros Corporation Irrigation solution and use thereof for the perioperative inhibition of pain/inflammation and/or spasm at a vascular structure
US5914316A (en) * 1994-12-16 1999-06-22 Washington University Method of inhibiting intimal hyperplasia
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
CA2214685C (en) 1995-03-10 2008-05-20 Berlex Laboratories, Inc. Benzamidine derivatives their preparation and their use as anti-coagulants
US5695760A (en) * 1995-04-24 1997-12-09 Boehringer Inglehiem Pharmaceuticals, Inc. Modified anti-ICAM-1 antibodies and their use in the treatment of inflammation
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5804376A (en) * 1995-05-02 1998-09-08 Incyte Pharmaceuticals, Inc. Pancreas-derived serpin
JPH11504938A (ja) 1995-05-08 1999-05-11 サイオス インク. クニッツ型プロテアーゼ阻害因子
ZA963619B (en) * 1995-05-08 1996-11-22 Scios Inc Protease inhibitor peptides
US5786328A (en) * 1995-06-05 1998-07-28 Genentech, Inc. Use of kunitz type plasma kallikrein inhibitors
US5780265A (en) * 1995-06-05 1998-07-14 Genentech, Inc. Kunitz type plasma kallikrein inhibitors
US6242414B1 (en) 1995-06-07 2001-06-05 Chiron Corporation Regulation of cytokine synthesis and release
US6126933A (en) 1995-06-27 2000-10-03 Genetics Institute Methods of treating inflammatory bowel diseases by administering IL-11
US5672662A (en) * 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
JPH0959838A (ja) 1995-08-24 1997-03-04 Kuraray Co Ltd 紡績糸
US6004579A (en) * 1995-09-14 1999-12-21 Lxr Biotechnology, Inc. Compositions which inhibit apoptosis, methods of making the compositions and uses thereof
JP2000500120A (ja) * 1995-09-21 2000-01-11 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデーション ポリ(エチレングリコール)と抗グルタミン酸デカルボキシラーゼ抗体の結合体の膵島細胞指向ターゲット化
US5736364A (en) * 1995-12-04 1998-04-07 Genentech, Inc. Factor viia inhibitors
CA2247888A1 (en) 1996-03-11 1997-09-18 Bayer Corporation Human bikunin
US6013763A (en) * 1996-06-04 2000-01-11 Genentech, Inc. Peptide variants of protein A
US5869637A (en) * 1996-07-22 1999-02-09 Incyte Pharmaceuticals, Inc. Human Kallikrein
DE19632772A1 (de) 1996-08-14 1998-02-19 Basf Ag Neue Benzamidine
US6214966B1 (en) 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
US6255455B1 (en) 1996-10-11 2001-07-03 The Trustees Of The University Of Pennsylvania Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof
US6258351B1 (en) 1996-11-06 2001-07-10 Shearwater Corporation Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels
AU5702298A (en) 1996-12-03 1998-06-29 Abgenix, Inc. Transgenic mammals having human Ig loci including plural VH and VK regions nd antibodies produced therefrom
CN1238366C (zh) 1997-01-21 2006-01-25 综合医院公司 利用rna-蛋白融合体筛选蛋白
US5840871A (en) * 1997-01-29 1998-11-24 Incyte Pharmaceuticals, Inc. Prostate-associated kallikrein
AU6042298A (en) 1997-01-31 1998-08-25 Human Genome Sciences, Inc. Tissue factor pathway inhibitor-3
US5962300A (en) 1997-03-26 1999-10-05 Incyte Pharmaceuticals, Inc. Human kallikrein
DE69833755T2 (de) 1997-05-21 2006-12-28 Biovation Ltd. Verfahren zur herstellung von nicht-immunogenen proteinen
US5990237A (en) * 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
WO1999034833A1 (en) 1998-01-07 1999-07-15 Shearwater Polymers, Incorporated Degradable heterobifunctional poly(ethylene glycol) acrylates and gels and conjugates derived therefrom
PT1061954E (pt) 1998-03-12 2004-10-29 Nektar Therapeutics Al Corp Derivados de poli(etileno glicol) com grupos reactivos proximos
DE69929311T2 (de) 1998-03-24 2006-09-07 Nof Corp. Oximanderivate und verfahren zu ihrer herstellung
US6017723A (en) * 1998-03-27 2000-01-25 Long Island Jewish Medical Center Method for isolating inhibitors of protease activity
JP2002510505A (ja) 1998-04-03 2002-04-09 フィロス インク. 位置特定可能な蛋白質アレイ
US6001596A (en) * 1998-05-07 1999-12-14 Incyte Pharmaceuticals, Inc. Growth-associated protease inhibitor heavy chain precursor
US6087473A (en) * 1999-05-26 2000-07-11 Zymogenetics, Inc. Kunitz domain polypeptide and materials and methods for making it
AU4229599A (en) 1998-06-03 1999-12-20 Scios Inc. Protease inhibitor peptides
US6034053A (en) 1998-07-13 2000-03-07 Wayne Hughes Institute EGF-isoflavone conjugates for the prevention of restenosis
US6783965B1 (en) 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
ES2404074T3 (es) 1998-08-06 2013-05-23 Mountain View Pharmaceuticals, Inc. Conjugados de peg-oxidasa de urato y su uso
CA2342072C (en) 1998-09-03 2005-01-11 Zymogenetics, Inc. Kunitz domain polypeptide zkun6
US7067144B2 (en) 1998-10-20 2006-06-27 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
US6114382A (en) 1998-11-11 2000-09-05 Moretti; Itagiba G. Methods for treating inflammatory bowel disease
CA2352538A1 (en) 1998-11-30 2000-06-08 Eli Lilly And Company Erythropoietic compounds
CN1202128C (zh) 1998-12-08 2005-05-18 拜奥威神有限公司 修饰蛋白的免疫原性
US6610503B1 (en) 1999-03-17 2003-08-26 Xenogen Corporation Animal models for predicting sepsis mortality
US20030012969A1 (en) 1999-04-06 2003-01-16 Clark Bert Thomas Soluble membrane strengthened paper products
US6605316B1 (en) 1999-07-31 2003-08-12 The Regents Of The University Of California Structures and fabrication techniques for solid state electrochemical devices
US6180607B1 (en) 1999-08-05 2001-01-30 Christopher Davies Protein having proteinase inhibitor activity
KR100942863B1 (ko) * 1999-08-24 2010-02-17 메다렉스, 인코포레이티드 인간 씨티엘에이-4 항체 및 그의 용도
HUP0203409A3 (en) 1999-11-12 2005-06-28 Maxygen Holdings Ltd Redwood C Interferon gamma conjugates
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
US6348558B1 (en) 1999-12-10 2002-02-19 Shearwater Corporation Hydrolytically degradable polymers and hydrogels made therefrom
US6544760B2 (en) 1999-12-22 2003-04-08 Zymogenetics, Inc. Kunitz domain polypeptide Zkun11
DK1259563T4 (en) 1999-12-22 2016-11-21 Nektar Therapeutics PROCEDURE FOR PREPARING 1-BENZOTRIAZOLYL CARBONATE ESTERS OF WATER SOLUBLE POLYMERS
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
US20020102703A1 (en) 1999-12-29 2002-08-01 Sheppard Paul O. Kunitz domain polypeptide zkun10
GB9930882D0 (en) 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
EP1274731A1 (en) 2000-03-13 2003-01-15 Eli Lilly And Company Human hepatocyte growth factor activator inhibitor homologue
EP1278544A4 (en) 2000-04-12 2004-08-18 Human Genome Sciences Inc ALBUMIN FUSION PROTEINS
CN1331213A (zh) 2000-06-30 2002-01-16 上海博德基因开发有限公司 一种新的多肽——人大蛋白10.01和编码这种多肽的多核苷酸
DE10034357C1 (de) 2000-07-14 2001-12-13 Elotherm Gmbh Verfahren und Vorrichtung zum Härten von Flächen an Bauteilen
BR0115020A (pt) 2000-10-31 2003-12-23 Deobiopharm S A Suspensão de uma proteìna epi-hne, processo de preparação da mesma, aerossol de pó seco derivado da mesma, composições farmacêuticas contendo a suspensão referida ou o aerossol referido, e suas aplicações
US20030113726A1 (en) 2000-12-04 2003-06-19 Zenta Tsuchihashi Human single nucleotide polymorphisms
TW593427B (en) 2000-12-18 2004-06-21 Nektar Therapeutics Al Corp Synthesis of high molecular weight non-peptidic polymer derivatives
JP2004531550A (ja) 2001-05-11 2004-10-14 アラダイム コーポレーション 吸入によって送達されるタンパク質の、分子性状の最適化方法および製剤
MXPA03010649A (es) 2001-05-21 2005-10-05 Nektar Therapeutics Administracion pulmonar de insulina modificada quimicamente.
US20040152633A1 (en) 2001-05-31 2004-08-05 Jorgensen Marianne Ulrich Kunitz-type sequences and polypeptides
WO2003033009A2 (en) 2001-07-10 2003-04-24 Omnio Ab Novel drug targets for arthritis
CN100366965C (zh) 2001-07-10 2008-02-06 日本电产三协株式会社 阀驱动设备
US6913900B2 (en) * 2001-08-29 2005-07-05 Nippon Zoki Pharmaceutical Co., Ltd. Plasma prekallikrein activation and kallikrein production assay
PT1438400E (pt) 2001-10-01 2009-09-10 Dyax Corp Vectores de apresentação eucarióticos de cadeias múltiplas e suas utilizações
WO2003035842A2 (en) 2001-10-24 2003-05-01 Dyax Corporation Hybridization control of sequence variation
JP4653915B2 (ja) 2001-10-29 2011-03-16 独立行政法人科学技術振興機構 全身性エリテマトーデスモデル非ヒト動物
KR100913714B1 (ko) 2001-11-08 2009-08-24 패시트 바이오테크 코포레이션 Igg 항체의 안정한 액상 약학 제형물
KR20110014661A (ko) 2002-02-07 2011-02-11 노보자임스 바이오파마 디케이 에이/에스 알부민-융합 쿠니츠 도메인 펩타이드
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
WO2003103475A2 (en) 2002-06-07 2003-12-18 Dyax Corp. Prevention and reduction of blood loss
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
RU2296769C2 (ru) 2002-07-24 2007-04-10 Ф.Хоффманн-Ля Рош Аг Пэгилированный полипептид т20
CN100337689C (zh) 2002-07-24 2007-09-19 弗·哈夫曼-拉罗切有限公司 聚亚烷基二醇酸加合物
SI2386310T1 (sl) 2002-08-28 2019-03-29 Dyax Corp. Metode za ohranjanje organov in tkiv
US20040062748A1 (en) 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US8129330B2 (en) 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US7314613B2 (en) 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
RS20050502A (en) 2002-12-26 2007-08-03 Mountain View Pharmaceuticals Inc., Polymer conjugates of interferon- beta with enhanced biological potency
US20040209243A1 (en) 2003-01-07 2004-10-21 Andrew Nixon Kunitz domain library
ES2311789T3 (es) 2003-01-08 2009-02-16 Novartis Vaccines And Diagnostics, Inc. Composiciones liofilizadas estabilizadas que comprenden inhibidor de la via del factor tisular o variantes del inhibidor de la via del factor tisular.
ATE424215T1 (de) 2003-01-08 2009-03-15 Novartis Vaccines & Diagnostic Stabilisierte wässrige zusammensetzungen mit gewebefaktorinhibitor (tfpi) oder gewebefaktorinhibitor-variante
US6989369B2 (en) 2003-02-07 2006-01-24 Dyax Corp. Kunitz domain peptides
GB0303085D0 (en) 2003-02-11 2003-03-19 Pfizer Ltd Model
CA2535859A1 (en) 2003-08-14 2005-03-03 Dyax Corp. Endotheliase-2 ligands
CA2537113A1 (en) 2003-08-29 2005-03-10 Dyax Corp. Modified protease inhibitors
WO2005021557A2 (en) 2003-08-29 2005-03-10 Dyax Corp. Poly-pegylated protease inhibitors
EP1674480A4 (en) * 2003-09-04 2007-06-20 Riken ANTIBODY RECOGNIZING THE REGIONAL SECTION CONTROLLING TGF-BETA ACTIVATION
WO2005027753A1 (en) 2003-09-19 2005-03-31 St. Jude Medical, Inc. Apparatus and methods for tissue gathering and securing
WO2005032556A1 (en) 2003-10-02 2005-04-14 Elan Pharmaceuticals, Inc. Method for reducing pain
US20060228331A1 (en) 2003-10-10 2006-10-12 Novo Nordisk A/S IL-21 Derivatives and variants
US20050164945A1 (en) 2003-10-21 2005-07-28 Andrew Nixon Endotheliase-1 ligands
US20070253949A1 (en) 2004-02-03 2007-11-01 Stefan Golz Diagnostics and Therapeutics for Diseases Associated with Plasma Kallikrein (KLKB1)
EP1807451A2 (en) 2004-08-03 2007-07-18 Dyax Corporation Hk1-binding proteins
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
JP2008520729A (ja) 2004-11-22 2008-06-19 ダイアックス コーポレーション プラスミン阻害療法
CN101102819A (zh) 2004-12-23 2008-01-09 Csl百灵有限公司 血栓的形成和/或稳定化的预防
US20060183771A1 (en) 2005-02-17 2006-08-17 Seiffert Dietmar A Novel combination of selective factor VIIa and/or factor XIa inhibitors and selective plasma kallikrein inhibitors
EP2295452A1 (en) 2005-05-04 2011-03-16 Zealand Pharma A/S Glucagon-like-peptide-2 (GLP-2) analogues
US20070079096A1 (en) 2005-09-30 2007-04-05 Chih-Wei Chen Data storage unit access authorization table automatic rebuilding method and system
PT1981519T (pt) 2005-12-29 2018-02-23 Dyax Corp Inibição de protéases
US7276480B1 (en) 2005-12-30 2007-10-02 Dyax Corp. Prevention and reduction of blood loss
CA2643693A1 (en) 2006-03-10 2007-09-20 Dyax Corp. Formulations for ecallantide
HUE031701T2 (en) 2006-03-16 2017-07-28 Dyax Corp Plasma kallikrein inhibiting peptides for use in treating eye diseases
EP1873344A1 (de) 2006-06-30 2008-01-02 Sika Technology AG Mittels Silikon agedichtete Verklebung
AU2007281220B2 (en) * 2006-07-31 2013-08-15 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
WO2008060764A2 (en) 2006-10-05 2008-05-22 Drugtech Corporation Topical therapies for oral mucositis and other conditions
KR100846354B1 (ko) 2007-03-21 2008-07-15 (주) 프로탄바이오 혈청 당단백질부터 분리한 폐암 진단용 마커
WO2009026334A2 (en) 2007-08-21 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
US20090105142A1 (en) 2007-08-23 2009-04-23 Genzyme Corporation Treatment with kallikrein inhibitors
US8359965B2 (en) 2007-09-17 2013-01-29 Oxford J Craig Apparatus and method for broad spectrum radiation attenuation
JP2011511647A (ja) 2008-02-13 2011-04-14 ダイアックス コーポレイション 特異的結合対を作製するための改善された方法
DE102008027574A1 (de) 2008-06-10 2009-12-17 Merck Patent Gmbh Neue Pyrrolidinderivate als MetAP-2 Inhibitoren
DE102008033095A1 (de) 2008-07-15 2010-01-28 Uhde Gmbh Vorrichtung zur Schlackeabführung aus einem Kohlevergasungsreaktor
CN102307594A (zh) * 2009-01-06 2012-01-04 戴埃克斯有限公司 用激肽释放酶抑制剂治疗粘膜炎
CN101928346B (zh) 2009-07-31 2013-01-16 华中科技大学同济医学院附属同济医院 一种抗人组织激肽释放酶单克隆抗体及其制备
HUE039605T2 (hu) 2010-01-06 2019-01-28 Dyax Corp Plazma kallikreint kötõ proteinek
KR102320178B1 (ko) 2011-01-06 2021-11-02 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질
WO2012142308A1 (en) 2011-04-13 2012-10-18 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
WO2012151247A2 (en) 2011-05-02 2012-11-08 Millennium Pharmaceuticals, Inc. FORMULATION FOR ANTI-α4β7 ANTIBODY
US9216219B2 (en) 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
PT2946206T (pt) 2013-01-20 2019-04-22 Dyax Corp Avaliação, ensaios e tratamento de distúrbios mediados por pkal
CA3209608A1 (en) 2013-01-20 2014-07-24 Takeda Pharmaceutical Company Limited Evaluation and treatment of pkal-mediated disorders
CA2906624A1 (en) 2013-03-15 2014-09-25 Dyax Corp. Anti-plasma kallikrein antibodies
KR20140119396A (ko) 2013-03-29 2014-10-10 삼성전자주식회사 단백질 약물의 액상 제형
CA2937329C (en) 2014-01-21 2022-05-31 Dyax Corp. Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema
WO2015148790A1 (en) 2014-03-27 2015-10-01 Dyax Corp. Compositions and methods for treatment of diabetic macular edema
EP3286226A4 (en) 2015-03-30 2018-12-05 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack
NZ744233A (en) 2015-12-11 2023-11-24 Takeda Pharmaceuticals Co Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
CA3133576A1 (en) 2019-03-14 2020-09-17 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack

Also Published As

Publication number Publication date
US20230340150A1 (en) 2023-10-26
LTC2521568I2 (lt) 2020-05-11
SI3459564T1 (sl) 2022-06-30
ES2688093T3 (es) 2018-10-30
FR19C1029I2 (fr) 2020-05-15
SI2521568T1 (sl) 2019-01-31
EP2521568A4 (en) 2013-06-12
CY1125705T1 (el) 2024-02-16
JP2017081919A (ja) 2017-05-18
JP6037841B2 (ja) 2016-12-07
JP2021006582A (ja) 2021-01-21
HUE039605T2 (hu) 2019-01-28
HUE057244T2 (hu) 2022-04-28
US20200109213A1 (en) 2020-04-09
JP6779944B2 (ja) 2020-11-04
US20180002448A1 (en) 2018-01-04
US8822653B2 (en) 2014-09-02
LTPA2019012I1 (lt) 2019-05-27
LUC00115I2 (nl) 2024-05-22
FR19C1029I1 (nl) 2019-06-21
WO2011085103A2 (en) 2011-07-14
CA3021759A1 (en) 2011-07-14
JP2018197234A (ja) 2018-12-13
CY2019020I1 (el) 2020-05-29
RS62853B1 (sr) 2022-02-28
CA2786019A1 (en) 2011-07-14
ES2905545T3 (es) 2022-04-11
JP6356199B2 (ja) 2018-07-11
PL3459564T3 (pl) 2022-04-19
PT3459564T (pt) 2022-01-31
EP2521568A2 (en) 2012-11-14
HRP20181419T1 (hr) 2018-11-16
US20180002447A1 (en) 2018-01-04
AU2011204349A1 (en) 2012-08-02
CA2786019C (en) 2018-12-18
HUS1900023I1 (hu) 2019-04-23
NL300986I1 (nl) 2019-05-15
EP3459564B1 (en) 2021-10-27
JP2022188112A (ja) 2022-12-20
NO2019020I1 (no) 2019-04-25
EP2521568B1 (en) 2018-07-25
PT2521568T (pt) 2018-10-26
LT3459564T (lt) 2022-03-10
PL2521568T3 (pl) 2019-03-29
EP4011917A1 (en) 2022-06-15
JP7146871B2 (ja) 2022-10-04
DK3459564T3 (da) 2022-02-07
JP2013516478A (ja) 2013-05-13
CA3168591A1 (en) 2011-07-14
CY2019020I2 (el) 2020-05-29
US10336832B2 (en) 2019-07-02
DK2521568T3 (en) 2018-11-19
AU2011204349C1 (en) 2017-02-16
US20110200611A1 (en) 2011-08-18
US20140335023A1 (en) 2014-11-13
US20180037664A1 (en) 2018-02-08
EP3459564A1 (en) 2019-03-27
US20180037666A1 (en) 2018-02-08
US20180002449A1 (en) 2018-01-04
US11505620B2 (en) 2022-11-22
US20180037665A1 (en) 2018-02-08
RS57870B1 (sr) 2018-12-31
AU2011204349B2 (en) 2014-09-04
LT2521568T (lt) 2018-12-10
HRP20220107T1 (hr) 2022-04-15
WO2011085103A3 (en) 2011-09-09
CY1122268T1 (el) 2020-05-29

Similar Documents

Publication Publication Date Title
BR112012028556A2 (pt) Indóis
DE102011100241A8 (de) Nitridhalbleiterbauteil
DK3225404T3 (da) Fluidpatron
CR20130111A (es) Triazina-oxidiazoles
DE10170954T8 (de) Mikrowellendruckgarer
DE112011104226A5 (de) Käfigmutter
DE102011117046A8 (de) Doppelkupplungswindungsgetriebe
DE112011102080A5 (de) Kupplungszentralausrücker
DE112011101226A5 (de) Linearwegmesssystem
DK2442899T3 (da) Rotorskive
DK2539163T3 (da) Dækventil
DE102011002623A8 (de) Ventilsteuerzeitversteller
DE112011102711A5 (de) Hydrostataktor
DK2448659T3 (da) Rotorskive
DK2447426T3 (da) Vaske-WC
DE102010019119B8 (de) Cuttermesser
DE112010005518A5 (de) Dichtungsmanchette
DE102010038420A8 (de) Reinigungungsvorrichtung
DK2596072T3 (da) Bor-forbindelses-suspension
DK2521486T3 (da) Palpometer
DE102010035554B8 (de) Fußtüröffner
CO6801789A2 (es) N-hetarilmetil pirazolilcarboxamidas
DE112011101796A5 (de) Redoxakkumulatoranlage
DK2404809T3 (da) Trækbjælke
DE112011104385A5 (de) Tierleiteinrichtung